Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
yes she still remains ceo...for now ..
however we still await the end of year results ..which are overdue imo.
the requisition notice really put a spanner in the works and has **cked the sp in the process as expected . many obvs thought the sp would rocket after that notice !.
what will the next rns be ?. . clx update ..., results, theoremrx update ( doubt it ) , agm announcement or that suzy is moving on.. so much news and updates are due but the bod remain silent while the sp slips yet again. . i just hope the shareholder observer observes the sp is ****e
She's turned out to be a complete and utter disaster for stakeholders. She should have been sacked for incompetence. Her legacy will be the saga known as Theorem. IMO.
Sean she is still employed at Valirx the least she could do is continue to do her job especially as she is still taking her salary although Personally I would have had her kicked out the company
Never a good idea if one is forcing board members to resign only to put himself on the board with no relevant experience. Not sure what everyone is expecting in this situation.
When Stella resigned one should have taken the position and then analysed what was going on. Based on that you would act.
Sorry about the spelling, either my thumbs are growing or my phone is shrinking!
Let’s have some perspective here!
She has just been ousted from here job, I understand your frustrations but you can hardly expect her to be oozing enthusiasm to a shareholder when its shareholders that have ousted her from her job, she isn’t perfect and was abvioisly inexperienced in a CEO role but don’t blame her for being human.
She’s a two faced rat
I've had a few correspondence emails with her but seems to have left the friendly attitude behind and not alot of explanations or response just hard nose you'll here about updates when the board decides through the normal channels ..
PJ
The Seawolf
Would not hurt to try…..
OB
There was a time when Dilly was known for her warm and reassuring responses to emails and many were taken in by the bollux she wrote. I wonder if she still responds but I suspect shes's run out of platitudes!
Has anyone emailed any of the Val email accounts listed on the website for general/investor enquiries. Was going to draft something asking some questions in relation to missed deadlines and lack of updates but thinking its not worth the hassle if I'm unlikely to get a response?
It isn't all about "tinpot",
A fully funded regulatory environment, a streamlined clinical trial process, higher tax incentives for research and European cooperation would all lead to better outcomes for patients.
Boris made a big speech promising change but this Government has delivered nothing.
Enough from me about politics.....back to waiting, as ever. 🙄
All those Brexit Benefits...
Its because tax are a tin pot company with no money
My point being, (before LSE crashed);
A change of Government, with full MHRA and NHS funding restored and a better European relationship (e.g. Horizon), remains our only hope.
Otherwise companies like Valirx will continue to suffer.
Just pop over to SAR and ask for their opinions of the MHRA!!
Ain't happening Fred,
In June 2021 Boris made a speech about restoring Britain as a scientific superpower, exactly the opposite has occurred.
In Nov 21 Valirx signed an LOI with Theoremrx and promised a "transformative year", exactly the opposite has occurred.
https://tinyurl.com/nhjnvtdj
Interesting chat regarding Dame Barbara's cancer...need to reduce cost of getting new drugs approved...change of approach required...use your treatments as an example Val
One post (two now) and three trades. WTF is going on?
Cheers Bob, saved me a job putting the f**kwit right.
Let's not forget the ValiRx mission statement to 'ACCELERATE the development of treatments in cancer and women’s health to improve patient lives'.
The harsh reality is that they are accelerating absolutely f**k all.
You are telling me. Feels like NNN did in its final days over here. It's Theorem that gets me the most. How can we just carry on like nothing happened, and like no promises were made in terms of updates. Ignore it and it will go away tactics being deployed. The only thing is everyone remembers and nobody will forget.
Somebody from the BOD needs to update the stakeholders.
A CLX timeline:
24 October 22 - Subsidiary launched
06 December 2022 - already commenced a full preclinical development
31 March 2023 - no immediate toxicology concerns
28 September 2023 - Opportunities for early partnering are being explored for Cytolytix, with active commercial development to promote the project to potential industry partners
Hardly, quick.
I couldn't even tell you where this asset is up to now, as the progress appears to be going backwards based on the last quarterly update. Unless the statement about early partnering was a bit of a fib ;-)
You keep giving the excuses though, eh!
pm2022
posts: 2,847
price: 3.45
strong buy
re: some good news today....today 16:28
quick to assume failure. this is drug development not some supermarket where you pick things from the shelf. trial and testing and timings are often over exaggerated.
still very much open could go either way but at this market cap only one success is needed for a multi bagger.
replyrecommendreport post
pm2020 for this your latest well researched , well educated post did you use the same research sources that you used to post buy at 35p++ no brainier with no down side?was it by any chance called recipe for the best bull**** to grow world class mushrooms 🤡🤡🤡🤡😂😂😂🤡🤡
Quick to assume failure. This is drug development not some supermarket where you pick things from the shelf. Trial and testing and timings are often over exaggerated.
Still very much open could go either way but at this market cap only one success is needed for a multi bagger.
I'm guessing the further CLX formulations haven't gone that well, considering the quarter referenced is now long gone.
From RNS dated 15th December 2023:
'CLX001 was placed in the single asset subsidiary company, Cytolytix Limited ("Cytolytix") in Q4 2022, and has undergone a programme of formulation development during H1 2023. The peptide active ingredient requires a nanoformulation to ensure that the peptide stabilised within the therapeutic agent and is delivered to cancer cells at appropriate levels.
The formulation development remains challenging, with further formulations being proposed and undergoing testing during the quarter.'